Nazi Germany's Tiger is arguably the most famous tank of

New Post Public Reply Private Reply Replies (0) Message Board
dw
85
Nazi Germany's Tiger is arguably the most famous tank of World War II. With its thick armor and devastating 88-millimeter gun, the Mark VI—or Tiger I—soon earned a devastating reputation on the battlefield.

Designed as a breakthrough tank for breaching enemy defenses, and allocated to a handful of special heavy tank battalions, the sixty-ton Tiger I seemed to have it all: firepower, armor and for an early 1940s vehicle that weighed as much as today's M-1 Abrams, it was fairly agile. With its square, castle-like shape and long cannon, the Tiger I even looked deadly. But Hitler's generals and weapons designers were not satisfied. With Teutonic perfectionism, they complained that the Tiger I's KwK 36 gun was not the most powerful version of the 88-millimeter cannon (not that Allied tankers would have noticed the difference). Even before the Tiger I debuted on the battlefield (floundering in the swamps near Leningrad in an ill-advised attack in September 1942), work had begun on a successor.

Enter the Tiger II, or Konigstiger (King Tiger). At seventy-five tons, it was bigger than its predecessor. Its longer-barreled (and thus higher velocity) KwK 43 88-millimeter cannon could penetrate five inches of armor at a range of two kilometers (1.2 miles). With Sherman and T-34 crews having about two inches of frontal armor between them and eternity, no wonder a supersized Tiger must have seemed the devil on treads.

The Tiger II also featured numerous improvements over the Tiger I. The original Tiger had vertical armor, rather than the more effective sloped armor (effectively increasing armor thickness) found on the T-34 and the later German Panther. The King Tiger had well-sloped armor that was six inches thick on the front hull. Its turret could traverse 360 degrees in nineteen seconds, compared to sixty seconds for the Tiger I, which had theoretically allowed a fast-moving Sherman or T-34 to maneuver behind a Tiger I faster than the German tank's gun could track it.

Like a professional football player, the Tiger II was more agile than it looked. It had a road speed of about twenty-five miles per hour, versus about thirty for the Sherman and T-34. Cross-country speed was about ten miles per hour, versus about twenty miles per hour for the other two tanks. Author Thomas Jentz, the dean of Tiger historians, writes that despite its size, the Tiger II had surprisingly good tactical mobility. Unlike the megalomaniacal 200-ton German Maus, which couldn't even roll over many European bridges, the King Tiger was a viable design.

Late war Germans tanks like the Tiger and Panther had a reputation for being over-engineered and mechanically finicky. As with any sophisticated weapon, the Tiger II did suffer from reliability issues, especially at the hands of the poorly trained and inexperienced tank drivers of the late war German army. But given a skilled crew and proper logistics support, the Tiger II was fairly reliable, according to Jentz. The problem was that by the time the King Tiger made its combat debut in Normandy in July 1944, the necessities that Nazi Germany most lacked was trained, experienced tank crews and fuel and logistics support.

Which brings us to the question dear to every treadhead: Was the King Tiger a great tank? As with all weapons, the answer is: it depends. In terms of the triad of metrics for tanks—firepower, armor and mobility—the Tiger II was quite impressive. It was probably better than its American rival, the lighter and less heavily armored forty-six-ton American M-26 Pershing. A more interesting question is the King Tiger versus the Soviet IS-2 Stalin tank. There are all sorts of conflicting data and opinions on this duel, though an encounter between IS-2s and King Tigers in August 1944 destroyed or damaged ten tanks on either side. One flaw of the IS-2, whose powerful 122-millimeter gun could theoretically penetrate a King Tiger's thickly armored turret at one-mile range—was its low rate of fire and limited onboard ammunition supply. Had the war continued until 1946, the King Tiger would probably have met its match in the British Centurion, one of the most successful tanks in history and still used today.

However, the most telling statistic is that while the Soviet Union produced nearly 3,900 IS-2s, Germany built just 492 Tiger IIs. The Soviets built more than 108,000 tanks, and the Americans eighty-eight thousand, because World War II was a contest of production that devoured material at an appalling rate. Less than 500 King Tigers, no matter how powerful, were not going to change the outcome.

Ironically, the King Tiger's most deadly predator wasn't other tanks, but Royal Air Force Lancaster bombers. The German army ordered 1,500 Tiger IIs, but RAF raids on manufacturer Henschel's factories slashed production. An earlier Tiger I cost 250,000 Reichsmarks, two to three times as much as smaller German tanks such as the Panther or Mark IV. Would Germany have been better off with a greater number of lighter tanks, especially the heavier Panther? Given the current American preference for expensive weapons like aircraft carriers and F-35 fighters, this question still resonates.

Weapons are extremely situational items. A tank that functions well in one setting might prove a failure in another. By the time the Tiger II made its combat debut in Normandy in July 1944, Germany was on the defensive. Big tanks like the King Tiger were mobile fortresses if properly sited in ambush positions. But on the attack, advancing down narrow, icy roads as the Tiger II did during the Battle of the Bulge, big, heavy fuel-guzzling tanks could be a liability. One problem with both the Tiger I and II was that they were so big relative to other German tanks, that the only vehicle that could tow a damaged Tiger was another Tiger. As the German armies retreated in the East and West, many of these behemoths were abandoned or blown up by their own crews.

Heavy tanks like the King Tiger proved a dead end. After 1945, nations switched to building main battle tanks that had sufficient firepower and armor to breach enemy defenses, like heavy tanks, while being mobile enough to exploit breakthroughs like medium and light tanks.

The day of the Tiger had passed.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 89

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 16

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Quest Diagnostics Faces Class Action After Data Breach

Updated Category News Views 36

Data Breach Rocks Quest Diagnostics October 2026 caught Quest Diagnostics in a bind they wish they could escape—a classic tech breach with personal info hanging out to dry. When a cyber ghost slipped into Quest's Quanum Lab Services Manager, it wasn't to deliver flowers. Nope, this unauthorized access was no friendly visit, forcing Quest to scream foul and play serious...

Continue Reading
Millrose Faces Securities Fraud Suit Amidst Decline

Updated Category News Views 148

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Continue Reading
John Wong's Decade as Estate Planning Specialist

Updated Category News Views 68

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 66

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
SLM Faces Legal Scrutiny as Losses Mount Amid Pause

Updated Category News Views 115

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 210

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Updated Category News Views 198

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Continue Reading
Tony Perkins' Church Tour amid Controversial Vote

Updated Category News Views 89

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Santander to Redeem €187.6 Million CoCos Efficiently

Updated Category News Views 146

Banco Santander Approaches €187.6 Million CoCos Redemption BANCO SANTANDER S.A. has made a significant announcement regarding the redemption of its contingent convertible securities (CoCos). This decision, which is seen as a strategic move, highlights the bank's commitment to financial efficacy and investor satisfaction. Additionally, the redemption covers a total...

Continue Reading
Revolutionizing ADC Characterization with Biozen Native Columns

Updated Category News Views 480

Transforming Biotherapeutic Characterization First of its Kind in Biotherapeutic Antibody Characterization Phenomenex Inc., a leader in separation science technology, has launched Biozen Native RP-1 and RP-5 chromatography columns. These innovative products are engineered to meet the growing demand for effective characterization methods for Antibody-Drug Conjugates...

Continue Reading
TG Therapeutics to Attend the Upcoming Global Healthcare Event

Updated Category News Views 274

Participation in Global Healthcare Conference TG Therapeutics, Inc. (NASDAQ: TGTX) is making waves as it prepares to take part in a prestigious healthcare event. Michael S. Weiss, the Chairman and CEO of the company, is scheduled to speak during the fireside chat at the Goldman Sachs Annual Global Healthcare Conference. This significant event will be hosted in Miami and...

Continue Reading
Ogury One: Revolutionizing Advertising in a Privacy-Centric World

Updated Category News Views 244

Ogury One: A New Era in Digital Advertising Ogury has launched its new client-facing platform, Ogury One, designed to revolutionize the way brands and agencies manage their advertising campaigns. As a leader in privacy-centric advertising solutions, Ogury One provides users with a comprehensive suite that facilitates seamless audience planning, activation, and reporting....

Continue Reading
Exploring Top Energy Stocks Benefiting from Industry Shifts

Updated Category News Views 124

Understanding the Shift in Energy Supply Dynamics The global energy landscape is undergoing significant changes, particularly as liquefied natural gas (LNG) supply anticipated an increase. Analysts believe that the next few years will see substantial growth in LNG, especially in response to evolving demand and new technologies. As the market adjusts, smart investors are...

Continue Reading